In the current study, we investigated changes in the inflammatory cardiovascular risk markers hepcidin-iron, FGF23-phosphate-klotho, and calprotectin pathways during 24 weeks of TRT in men with T2D; secondarily, we investigated whether possible changes in inflammatory markers during TRT could be a direct or indirect effect. The gene discussed is FGF23; the disease is type 2 diabetes mellitus.